Piper Sandler Raises Roivant Sciences (NASDAQ:ROIV) Price Target to $22.00

Roivant Sciences (NASDAQ:ROIV) had its target price boosted by Piper Sandler from $20.00 to $22.00 in a research note issued to investors on Wednesday, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Other equities research analysts also recently issued reports about the company. Cantor Fitzgerald reiterated an overweight rating on shares of Roivant Sciences in a research report on Tuesday, June 18th. HC Wainwright reaffirmed a buy rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Friday, May 31st. Truist Financial reissued a buy rating and issued a $23.00 target price on shares of Roivant Sciences in a report on Monday, March 25th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Roivant Sciences from $14.00 to $15.00 and gave the company a buy rating in a research note on Wednesday, April 3rd. Finally, The Goldman Sachs Group lifted their price objective on shares of Roivant Sciences from $16.00 to $18.00 and gave the stock a buy rating in a research note on Wednesday, April 3rd. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $17.10.

Roivant Sciences Trading Up 1.0 %

ROIV stock opened at $11.35 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 25.24 and a quick ratio of 25.24. Roivant Sciences has a 1-year low of $8.24 and a 1-year high of $13.24. The business has a 50 day simple moving average of $10.90 and a two-hundred day simple moving average of $10.89. The company has a market capitalization of $8.38 billion, a price-to-earnings ratio of 2.24 and a beta of 1.24.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Thursday, May 30th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.03. The company had revenue of $28.93 million during the quarter, compared to analysts’ expectations of $32.46 million. Roivant Sciences had a net margin of 3,484.86% and a negative return on equity of 25.05%. Research analysts anticipate that Roivant Sciences will post -1.12 EPS for the current fiscal year.

Institutional Trading of Roivant Sciences

Several institutional investors have recently added to or reduced their stakes in ROIV. FNY Investment Advisers LLC purchased a new stake in shares of Roivant Sciences in the fourth quarter worth approximately $33,000. Headlands Technologies LLC bought a new stake in shares of Roivant Sciences during the fourth quarter worth $36,000. Allspring Global Investments Holdings LLC lifted its position in shares of Roivant Sciences by 42.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 5,385 shares of the company’s stock worth $60,000 after purchasing an additional 1,608 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Roivant Sciences during the first quarter valued at $72,000. Finally, Premier Path Wealth Partners LLC bought a new position in shares of Roivant Sciences in the first quarter worth about $126,000. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.